Firefly Neuroscience, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $20.4M
- Price
- $1.20
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.44%
- Volume
- 71.4K
About
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.
Quick stats
Shares outstanding15.6M
Computed float13.0M
Float / shares83.8%
Cash runway (months)1
Key info
SectorTechnology
IndustrySoftware - Application
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000803578
Websitehttps://fireflyneuro.com
AI Summary
AI-generated1/5
standardbullishoperations update
Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
Firefly Neuroscience reported a 291% year-over-year increase in clinical assessments performed by TMS center customers using its FDA-cleared Evoke platform.
The Evoke system utilizes AI-powered EEG/ERP scans to help clinicians identify patterns associated with depression, anxiety, and ADHD, allowing for more precise treatment planning.
CEO Greg Lipschitz noted that the expansion validates the company's growth strategy and highlights the platform's ability to provide objective evidence of treatment efficacy.